Sionna Therapeutics (SION) Competitors

$42.77 -0.35 (-0.81%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$42.71 -0.06 (-0.14%)

As of 05/14/2026 07:06 PM Eastern

SION vs. QGEN, KYMR, ACLX, MIRM, and PTGX

Should you buy Sionna Therapeutics stock or one of its competitors? MarketBeat compares Sionna Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sionna Therapeutics include Qiagen (QGEN), Kymera Therapeutics (KYMR), Arcellx (ACLX), Mirum Pharmaceuticals (MIRM), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry.

How does Sionna Therapeutics compare to Qiagen?

Qiagen (NYSE:QGEN) and Sionna Therapeutics (NASDAQ:SION) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

Qiagen has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market.

Qiagen presently has a consensus target price of $46.38, suggesting a potential upside of 39.25%. Sionna Therapeutics has a consensus target price of $53.00, suggesting a potential upside of 23.92%. Given Qiagen's higher probable upside, research analysts plainly believe Qiagen is more favorable than Sionna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	0 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Sionna Therapeutics	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.91

Qiagen has higher revenue and earnings than Sionna Therapeutics. Sionna Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.28	$424.88M	$1.91	17.44
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A

In the previous week, Sionna Therapeutics had 8 more articles in the media than Qiagen. MarketBeat recorded 24 mentions for Sionna Therapeutics and 16 mentions for Qiagen. Qiagen's average media sentiment score of 0.23 beat Sionna Therapeutics' score of -0.15 indicating that Qiagen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	2 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Sionna Therapeutics	4 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

70.0% of Qiagen shares are owned by institutional investors. 9.0% of Qiagen shares are owned by company insiders. Comparatively, 3.9% of Sionna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Qiagen has a net margin of 19.16% compared to Sionna Therapeutics' net margin of 0.00%. Qiagen's return on equity of 14.40% beat Sionna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Sionna Therapeutics	N/A	-27.31%	-25.88%

Summary

Qiagen beats Sionna Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Sionna Therapeutics compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Sionna Therapeutics (NASDAQ:SION) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

Kymera Therapeutics has a beta of 2.06, meaning that its share price is 106% more volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market.

Sionna Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Sionna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Sionna Therapeutics	N/A	-27.31%	-25.88%

Sionna Therapeutics has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	177.28	-$311.35M	-$3.57	N/A
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A

In the previous week, Sionna Therapeutics had 16 more articles in the media than Kymera Therapeutics. MarketBeat recorded 24 mentions for Sionna Therapeutics and 8 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.32 beat Sionna Therapeutics' score of -0.15 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sionna Therapeutics	4 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Kymera Therapeutics presently has a consensus target price of $118.10, suggesting a potential upside of 39.76%. Sionna Therapeutics has a consensus target price of $53.00, suggesting a potential upside of 23.92%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kymera Therapeutics is more favorable than Sionna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96
Sionna Therapeutics	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.91

Summary

Kymera Therapeutics beats Sionna Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Sionna Therapeutics compare to Arcellx?

Arcellx (NASDAQ:ACLX) and Sionna Therapeutics (NASDAQ:SION) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

Arcellx has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market.

96.0% of Arcellx shares are owned by institutional investors. 8.4% of Arcellx shares are owned by insiders. Comparatively, 3.9% of Sionna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Sionna Therapeutics has a net margin of 0.00% compared to Arcellx's net margin of -1,027.26%. Sionna Therapeutics' return on equity of -27.31% beat Arcellx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcellx	-1,027.26%	-55.42%	-36.24%
Sionna Therapeutics	N/A	-27.31%	-25.88%

Sionna Therapeutics has lower revenue, but higher earnings than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcellx	$22.29M	301.95	-$228.93M	-$4.07	N/A
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A

In the previous week, Sionna Therapeutics had 24 more articles in the media than Arcellx. MarketBeat recorded 24 mentions for Sionna Therapeutics and 0 mentions for Arcellx. Arcellx's average media sentiment score of 1.07 beat Sionna Therapeutics' score of -0.15 indicating that Arcellx is being referred to more favorably in the media.

Company	Overall Sentiment
Arcellx	Positive
Sionna Therapeutics	Neutral

Arcellx presently has a consensus target price of $111.87, suggesting a potential downside of 2.78%. Sionna Therapeutics has a consensus target price of $53.00, suggesting a potential upside of 23.92%. Given Sionna Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sionna Therapeutics is more favorable than Arcellx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcellx	1 Sell rating(s)	16 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.11
Sionna Therapeutics	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.91

Summary

Sionna Therapeutics beats Arcellx on 12 of the 16 factors compared between the two stocks.

How does Sionna Therapeutics compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Sionna Therapeutics (NASDAQ:SION) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Mirum Pharmaceuticals currently has a consensus price target of $136.42, indicating a potential upside of 22.47%. Sionna Therapeutics has a consensus price target of $53.00, indicating a potential upside of 23.92%. Given Sionna Therapeutics' higher probable upside, analysts clearly believe Sionna Therapeutics is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
Sionna Therapeutics	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.91

Mirum Pharmaceuticals has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market.

Sionna Therapeutics has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Sionna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Sionna Therapeutics	N/A	-27.31%	-25.88%

Mirum Pharmaceuticals has higher revenue and earnings than Sionna Therapeutics. Sionna Therapeutics is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	13.03	-$23.36M	-$13.61	N/A
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A

In the previous week, Mirum Pharmaceuticals and Mirum Pharmaceuticals both had 24 articles in the media. Mirum Pharmaceuticals' average media sentiment score of 0.67 beat Sionna Therapeutics' score of -0.15 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Sionna Therapeutics	4 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Mirum Pharmaceuticals beats Sionna Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Sionna Therapeutics compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Sionna Therapeutics (NASDAQ:SION) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Protagonist Therapeutics has a beta of 1.89, meaning that its stock price is 89% more volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market.

98.6% of Protagonist Therapeutics shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 3.9% of Sionna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Protagonist Therapeutics currently has a consensus price target of $113.69, indicating a potential upside of 7.71%. Sionna Therapeutics has a consensus price target of $53.00, indicating a potential upside of 23.92%. Given Sionna Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sionna Therapeutics is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Sionna Therapeutics	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.91

Sionna Therapeutics has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Sionna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Sionna Therapeutics	N/A	-27.31%	-25.88%

Sionna Therapeutics has lower revenue, but higher earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	147.50	-$130.15M	-$1.81	N/A
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A

In the previous week, Sionna Therapeutics had 9 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 24 mentions for Sionna Therapeutics and 15 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.22 beat Sionna Therapeutics' score of -0.15 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sionna Therapeutics	4 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Protagonist Therapeutics beats Sionna Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Sionna Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SION and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SION vs. The Competition

Export

Metric	Sionna Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.95B	$3.42B	$6.34B	$12.37B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-22.16	18.47	20.66	25.63
Price / Sales	N/A	294.84	547.02	76.59
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	6.70	6.93	9.93	6.97
Net Income	-$75.27M	$24.11M	$3.55B	$333.62M
7 Day Performance	-3.30%	5.89%	1.69%	1.09%
1 Month Performance	-5.15%	-0.91%	0.48%	3.08%
1 Year Performance	218.23%	74.58%	39.38%	35.68%

Sionna Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SION Sionna Therapeutics	2.3574 of 5 stars	$42.77 -0.8%	$53.00 +23.9%	+256.4%	$1.95B	N/A	N/A	35	Earnings Report Analyst Forecast
QGEN Qiagen	4.5679 of 5 stars	$33.50 -2.7%	$46.38 +38.4%	-23.3%	$7.10B	$2.09B	17.50	5,654	Dividend Increase Analyst Downgrade
KYMR Kymera Therapeutics	2.3799 of 5 stars	$84.63 -1.9%	$118.10 +39.5%	+184.0%	$7.10B	$39.21M	N/A	170
ACLX Arcellx	2.5026 of 5 stars	$115.07 flat	$111.87 -2.8%	+95.0%	$6.73B	$22.29M	N/A	80	High Trading Volume
MIRM Mirum Pharmaceuticals	2.4168 of 5 stars	$102.93 -6.5%	$136.42 +32.5%	+150.9%	$6.71B	$521.31M	N/A	140	Analyst Revision High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SION) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sionna Therapeutics (SION) Competitors

SION vs. QGEN, KYMR, ACLX, MIRM, and PTGX

How does Sionna Therapeutics compare to Qiagen?

Summary

How does Sionna Therapeutics compare to Kymera Therapeutics?

Summary

How does Sionna Therapeutics compare to Arcellx?

Summary

How does Sionna Therapeutics compare to Mirum Pharmaceuticals?

Summary

How does Sionna Therapeutics compare to Protagonist Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SION vs. The Competition

Sionna Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sionna Therapeutics (SION) Competitors

SION vs. QGEN, KYMR, ACLX, MIRM, and PTGX

How does Sionna Therapeutics compare to Qiagen?

Which has more risk & volatility, QGEN or SION?

Do analysts recommend QGEN or SION?

Which has higher earnings and valuation, QGEN or SION?

Does the media favor QGEN or SION?

Do institutionals and insiders hold more shares of QGEN or SION?

Is QGEN or SION more profitable?

Summary

How does Sionna Therapeutics compare to Kymera Therapeutics?

Which has more risk & volatility, KYMR or SION?

Is KYMR or SION more profitable?

Which has stronger earnings & valuation, KYMR or SION?

Does the media refer more to KYMR or SION?

Do analysts recommend KYMR or SION?

Summary

How does Sionna Therapeutics compare to Arcellx?

Which has more volatility and risk, ACLX or SION?

Do insiders & institutionals hold more shares of ACLX or SION?

Is ACLX or SION more profitable?

Which has stronger earnings & valuation, ACLX or SION?

Does the media favor ACLX or SION?

Do analysts recommend ACLX or SION?

Summary

How does Sionna Therapeutics compare to Mirum Pharmaceuticals?

Do analysts recommend MIRM or SION?

Which has more volatility and risk, MIRM or SION?

Is MIRM or SION more profitable?

Which has stronger valuation & earnings, MIRM or SION?

Does the media favor MIRM or SION?

Summary

How does Sionna Therapeutics compare to Protagonist Therapeutics?

Which has more volatility & risk, PTGX or SION?

Do institutionals and insiders believe in PTGX or SION?

Do analysts recommend PTGX or SION?

Is PTGX or SION more profitable?

Which has stronger valuation & earnings, PTGX or SION?

Does the media prefer PTGX or SION?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SION vs. The Competition

Sionna Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools